Tumor inhibition by metallocenes: antitumor activity of titanocene dihalides (C5H5)2TiX2 (X=F, Cl, Br, I, NCS) and their application in buffered solutions as a method for suppressing drug-induced side effects
- PMID: 7400205
- PMCID: PMC12253507
- DOI: 10.1007/BF00411276
Tumor inhibition by metallocenes: antitumor activity of titanocene dihalides (C5H5)2TiX2 (X=F, Cl, Br, I, NCS) and their application in buffered solutions as a method for suppressing drug-induced side effects
Abstract
The antitumor activity of titanocene dihalides (C5H5)2TiX2 with X=F, Cl, Br, I, NCS is investigated against Ehrlich ascites tumor in CF 1 mice. Varying doses of the compounds are applied as single i.p. injections 24 h p.t.t. both in non-buffered (pH 1.4-3.9) and buffered (pH 4.2-5.9) solutions or suspensions, all of the substances achieving in optimum doses cure rates of 100% on day 120 p.t.t. This corresponds to I.L.S. values of 600-750% referred to the untreated controls. Some drug-induced side effects, especially the appearance of postperitonitic symptoms several weeks after i.p. application of higher doses of titanocene dihalides, are strikingly reduced by pH elevation in the injected drug solutions.
Die tumorhemmende Wirksamkeit von Titanocen-dihalogeniden (C5H5)2TiX2 mit X=F, Cl, Br, J, NCS wird an Ehrlich-Aszites-Tumor-tragenden CF 1-Mäusen untersucht. Verschiedene Dosen der Substanzen werden 24 h p.t.t. als einmalige i.p.-Injektionen sowohl in ungepufferten (pH 1.4–3.9) als auch in gepufferten (pH 4.2–5.9) Lösungen bzw. Suspensionen appliziert. Mit allen Verbindungen werden in optimaler Dosis Heilungsraten von 100% am 120. Tag p.t.t. erreicht. Dies entspricht Verlängerungen der mittleren Überlebensdauer (I.L.S.-Werte) um 600–750% gegenüber den unbehandelten Kontrolltieren. Einige substanzbedingte Nebenwirkungen, insbesondere das Auftreten postperitonitischer Symptome mehrere Wochen nach i.p.-Applikation höherer Dosen der Titanocen-dihalogenide, werden durch pH-Erhöhung in den Injektionslösungen deutlich zurückgedrängt.
Similar articles
-
Antitumor activity of ionic niobocene and molybdenocene complexes in high oxidation states.J Cancer Res Clin Oncol. 1992;118(3):216-21. doi: 10.1007/BF01410137. J Cancer Res Clin Oncol. 1992. PMID: 1548287 Free PMC article.
-
[Tumor inhibition by metallocenes: effect of titanocene, zirconocene, and hafnocene dichlorides on Ehrlich ascites tumor in mice (author's transl)].J Cancer Res Clin Oncol. 1980 Jan;96(1):43-51. doi: 10.1007/BF00412896. J Cancer Res Clin Oncol. 1980. PMID: 7188941 Free PMC article. German.
-
Tumor inhibition by titanocene complexes: influence upon two xenografted human lung carcinomas.J Cancer Res Clin Oncol. 1987;113(4):342-8. doi: 10.1007/BF00397717. J Cancer Res Clin Oncol. 1987. PMID: 3036884 Free PMC article.
-
The Black Book of Psychotropic Dosing and Monitoring.Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
-
Perioperative administration of buffered versus non-buffered crystalloid intravenous fluid to improve outcomes following adult surgical procedures.Cochrane Database Syst Rev. 2017 Sep 21;9(9):CD004089. doi: 10.1002/14651858.CD004089.pub3. Cochrane Database Syst Rev. 2017. PMID: 28933805 Free PMC article.
Cited by
-
Ionic titanocene complexes: a new type of antitumor agent.Cancer Chemother Pharmacol. 1989;24(1):23-7. doi: 10.1007/BF00254100. Cancer Chemother Pharmacol. 1989. PMID: 2720888
-
In Search for Titanocene Complexes with Improved Cytotoxic Activity: Synthesis, X-Ray Structure, and Spectroscopic Study of Bis(eta-cyclopentadienyl)difluorotitanium(IV).Bioinorg Chem Appl. 2010;2010:914580. doi: 10.1155/2010/914580. Epub 2010 Jun 23. Bioinorg Chem Appl. 2010. PMID: 20689714 Free PMC article.
-
In vitro cell growth inhibition by metallocene dichlorides.Cancer Chemother Pharmacol. 1981;5(4):237-41. doi: 10.1007/BF00434391. Cancer Chemother Pharmacol. 1981. PMID: 7261252
-
Organometallic anticancer compounds.J Med Chem. 2011 Jan 13;54(1):3-25. doi: 10.1021/jm100020w. Epub 2010 Nov 15. J Med Chem. 2011. PMID: 21077686 Free PMC article. Review. No abstract available.
-
Antitumor activity of ionic niobocene and molybdenocene complexes in high oxidation states.J Cancer Res Clin Oncol. 1992;118(3):216-21. doi: 10.1007/BF01410137. J Cancer Res Clin Oncol. 1992. PMID: 1548287 Free PMC article.
References
-
- Cleare MJ (1974) Transition metal complexes in cancer chemotherapy. Coord Chem Rev 12:349–405
-
- Köpf H, Block B, Schmidt M (1968) Di-π-cyclopentadienyl-titan(IV)-pentaselenid und-pentasulfid, zwei Hetero-cyclohexachalkogene in fixierter Konformation. Chem Ber 101:272–276
-
- Köpf H, Köpf-Maier P (1979) Titanocen-dichlorid — das erste Metallocen mit cancerostatischer Wirksamkeit. Angew Chem 91:509; Angew Chem Int Ed Engl 18:477–478 - PubMed
-
- Köpf-Maier P, Köpf H (1979) Vanadocen-dichlorid — ein weiteres Antitumor-Agens aus der Metallocenreihe. Z Naturforsch 34b:805–807
-
- Köpf-Maier P, Leitner M, Voigtländer R, Köpf H (1979) Molybdocen-dichlorid als Antitumor-Agens. Z Naturforsch 34c:1174–1176 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources